# An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine

> **NCT02985398** · PHASE3 · COMPLETED · sponsor: **Alder Biopharmaceuticals, Inc.** · enrollment: 128 (actual)

## Conditions studied

- Migraine Disorder

## Interventions

- **BIOLOGICAL:** ALD403 (Eptinezumab)

## Key facts

- **NCT ID:** NCT02985398
- **Lead sponsor:** Alder Biopharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12
- **Primary completion:** 2018-04
- **Final completion:** 2019-03
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2020-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02985398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02985398, "An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02985398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*